GlomCon Hawaii August 1 - 2026 Supporting materials POSTER: Treatment Experiences and Expectations in IgA Nephropathy: Patient and Clinician Perspectives on Current Management and Emerging Therapies ORAL PRESENTATION: Effect of Sibeprenlimab on Circulating Immune Complexes in Adults With IgA Nephropathy in the Phase 3 VISIONARY Trial ORAL PRESENTATION: Sibeprenlimab in IgA Nephropathy: Topline 24-Month eGFR Results ORAL PRESENTATION: Understanding the Patient Journey in IgA Nephropathy: Patient and Clinician Perspectives on Diagnostic Delays and Opportunities for Earlier Intervention
